FOXP3 and cancer: As an alternative cancer immunotherapeutic strategy, small molecules targeting FoxP3 in Tregs could achieve higher effects than biologicals and macromolecules due to their ability to cross the cell membrane, their easier penetration into the TME, and their possible oral availability.